Physician profile
Jae Lee
NPI 1073776985
$3,306.11
in general payments reported to CMS, 2019-2025
29 companies · $969 in 2025
The $969 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $827 · 2022: $136 · 2023: $755 · 2024: $620 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $835.09 | 2021-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $370.80 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.01 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $248.22 | 2022-2025 | Entyvio, Eohilia, Fruzaqla |
| Mallinckrodt Hospital Products INC. | $232.20 | 2022-2025 | Terlivaz |
| Daiichi Sankyo INC. | $147.29 | 2022-2024 | Injectafer |
| Abbvie INC. | $127.74 | 2022-2025 | |
| Janssen Biotech, INC. | $125.58 | 2023-2024 | Stelara, Talvey |
| Ipsen Biopharmaceuticals, INC | $118.21 | 2025 | Iqirvo |
| Karyopharm Therapeutics INC. | $117.93 | 2023 | Xpovio |
| Secura Bio, INC. | $106.21 | 2021 | |
| Intercept Pharmaceuticals, INC. | $97.38 | 2023-2024 | Ocaliva |
| Shield Therapeutics INC | $66.70 | 2023-2024 | Accrufer |
| Qol Medical, LLC | $36.65 | 2024 | Sucraid |
| Aimmune Therapeutics, INC. | $34.96 | 2025 | Vowst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.51 | 2025 | Wegovy |
| Sandoz INC. | $29.63 | 2024 | Hyrimoz |
| Ardelyx, INC. | $25.24 | 2025 | Ibsrela |
| Genentech USA, INC. | $24.62 | 2023 | Alecensa, Tecentriq, Gavreto |
| Exact Sciences Corporation | $23.23 | 2025 | The Cologuard Plus Collection Kit |
| Ironwood Pharmaceuticals, INC | $22.68 | 2023 | Linzess |
| Pfizer INC. | $22.41 | 2025 | |
| Organon LLC | $22.40 | 2023 | Hadlima, Renflexis |
| Pharmacosmos Therapeutics INC. | $22.29 | 2023 | Monoferric |
| Merck Sharp & Dohme LLC | $18.99 | 2023 | Dificid, Zinplava |
| W. L. Gore & Associates, INC. | $18.89 | 2023 | Gore Cardioform Septal Occluder |
| Regeneron Healthcare Solutions, INC. | $17.28 | 2025 | Dupixent |
| Orphalan INC | $14.88 | 2025 | Cuvrior |
| Lilly USA, LLC | $14.09 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.